Skip to main content
. 2019 Sep 4;4:129. [Version 1] doi: 10.12688/wellcomeopenres.15408.1

Figure 3. The possible co-payments required by patients for the hepatitis C virus (HCV) drugs.

Figure 3.

The values summarize the different potential co-payment rates by patients for the HCV drugs (based on Figure 3). Note, these only pertain to the drugs and not the other resources/services.